Nearly 3 million people in the United States and 65 million people worldwide have epilepsy, a neurological condition which affects the nervous system and causes seizures. One in 26 people will develop epilepsy at some point in their lifetime, with 150,000 new cases annually in the United States. Nearly 80% of the people with epilepsy live in low- and middle-income countries and three-quarters of these individuals do not get the treatment they need.
Among those living with epilepsy, nearly one-third have ongoing seizures despite existing therapies. Each year, more than 1 out of 1,000 people with epilepsy die from sudden unexpected death in epilepsy (SUDEP). If seizures are uncontrolled, the risk of SUDEP increases to more than 1 out of 150. SUDEP is the leading cause of death in young adults with uncontrolled seizures.
In order to accelerate the identification of effective treatments for SUDEP, the Epilepsy Foundation SUDEP Institute is sponsoring a Reduction to Practice Challenge to develop a predictive biomarker or panel of biomarkers to identify people at risk for SUDEP or seizures that compromise cardiac or respiratory function. The biomarker(s) must serve as an endpoint or surrogate endpoint that will drive human SUDEP interventions. For example, the biomarker(s) may identify a high risk patient group that could be used to test existing candidate interventions such as seizure detection devices.
Milestone 1 requires a detailed Project Plan of the proposed solution. Milestone 2 involves the production of proof-of-concept data. Milestone 3 requires results that demonstrate the predictive efficacy of the biomarker(s). The SUDEP Institute intends to make up to 10 awards from a total award pool of $100,000 for Milestone 1, up to 4 awards of $25,000 each for Milestone 2, and a final award at least $800,000 for successful completion of Milestone 3.
Solvers are encouraged to enter this Challenge even if they were not involved in The SUDEP Institute Challenge: Predictive Biomarkers of Epilepsy – Challenge 9933719. Participants from the previous Challenge may elect to expound upon their (winning) solution or pursue another idea. Solvers should note that the Center for SUDEP Research (CSR) is an NIH-funded research collaborative studying animal models of SUDEP and epilepsy patients who may be at high risk for SUDEP. Solvers may contact the CSR at email@example.com to request data and/or biospecimens to be used in the execution of a Solution. Other resources that Solvers may access are through the North American SUDEP Registry and the Center for Disease Control and Prevention (CDC) Sudden Death in the Young Registry.
This is a Reduction to Practice Challenge that requires written documentation, experimental proof-of-concept data, and biomarker validation data.
Source: InnoCentive Challenge ID: 9933784
Advanced Septic Nitrogen Sensor Challenge
The U.S. Environmental Protection Agency (USEPA) (the Seeker) in collaboration with the U.S. Geological Survey (USGS) and The Nature Conservancy (TNC) seeks to identify and spur development of technologies to monitor nitrogen concentration in effluent from advanced Onsite Wastewater Treatment Systems (OWTS). Phase I of this Challenge program is an Ideation Challenge to gain a better understanding of low cost sensor technology that could be utilized to detect and measure nitrate and ammonium, or total nitrogen in the effluent of advanced OWTS. If this initial Ideation is successful, future phases of the Septic Challenge program will include prototype development and testing.
This is an Ideation Challenge with a guaranteed award for at least one submitted solution.
Source: InnoCentive Challenge ID: 9933926
Arsenic Sensor Challenge – Stage 1
This Challenge seeks to identify new or improved sensors, devices, or test kits to test for arsenic in water within natural and engineered systems. Solutions must improve on the current arsenic measurement methods. Areas of needed improvement include: performance, ease of use, reduction in hazardous waste production, data interpretation, and cost. This is Stage 1 of a planned two-stage Challenge, with the second stage consisting of a prototype demonstration and a larger prize purse. Bureau of Reclamation (Reclamation) is the Seeker for this Challenge. The U.S. Environmental Protection Agency, Xylem, Inc., the Indian Health Service, the National Institute of Standards and Technology, the U.S. Agency for International Development, the Agricultural Research Service, and the U.S. Geological Survey collaborated with Reclamation on various aspects of this Challenge.
This web site is hosted by a private entity and is not a service of Reclamation, Xylem, EPA, or the Department of the Interior (DOI). The solicitation and collection of your personal or individually identifiable information is subject to the host’s privacy and security policies and will only be shared with Reclamation if you win the Challenge. Challenge winners’ personally identifiable information must be made available to Reclamation in order to collect an award. Please consult the Challenge-Specific Agreement.
Source: InnoCentive Challenge ID: 9933765
Coccidiosis Prevention and Control in Poultry
The poultry industry sustains significant losses each year due to coccidiosis. Young birds are especially vulnerable to pathogenic infections as it takes several months for their immune systems to mature after birth. Prevention of coccidiosis can be achieved with drugs that either kill the parasites or prevent their growth and replication within the gastrointestinal tract. The use of anticoccidial medicines has led to drug-resistant strains, therefore, Elanco is searching for novel approaches to prevent, treat, or control coccidiosis in poultry.
A webinar presented by Elanco and InnoCentive concerning Elanco’s Grand Challenge Program was held on October 20, 2016. A recording of the session can be accessed here.
This Theoretical Challenge requires only a written proposal.
Source: InnoCentive Challenge ID: 9933890
Prevention and Control of Enteropathy/Ileitis in Swine
Proliferative enteropathy, commonly known as “ileitis” is the most common enteric disease in pigs. Various antibiotics and vaccination strategies are used to control and treat the disease, but recent changes in regulatory policies and pressure from consumers regarding the use of antibiotics in livestock have increased the need for alternative methods to control the disease. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of proliferative enteropathy in swine.
Source: InnoCentive Challenge ID: 9933892
Overcoming Key Burden Factors of Patient Participation in Clinical Trials
Deciding to participate in a clinical trial is a complex decision that requires a patient to weigh the pros and cons of potential medical benefit vs. the unknown risks of side effects plus the time, effort and commitment needed to comply with the study protocol. Once in a clinical trial, the burdens of participation may lead to excessive physical and mental stress, which can adversely affect the patient’s well-being and could cause him or her to drop out of a trial prematurely or prevent him or her from enrolling in additional studies. Allergan is committed to improving the patient experience and therefore desires new approaches to overcome key burdens associated with clinical trial participation.
Source: InnoCentive Challenge ID: 9933940
Liver abscesses are lesions that can develop in all cattle, regardless of age, gender, or breed. Since affected cattle seldom exhibit clinical signs, abscesses are only detected at harvest, where they contribute significantly to loss in carcass value. Although many factors impact the incidence of abscess development, the primary etiological agent is thought to be a bacterial infection. Therefore, cattle are fed tylosin, a broad spectrum, shared-class antibiotic. In an effort to develop antibiotic alternatives, Elanco desires an animal model that recapitulates liver abscess formation in ruminants.
Source: InnoCentive Challenge ID: 9933889
Enteric diseases in poultry result in a number of problems including food safety, performance losses, and increased mortality. Necrotic enteritis is one of the most common enteric diseases in poultry and the worldwide annual loss is estimated to be over $2 billion. Therefore, Elanco desires novel approaches for the prevention, treatment, or control of necrotic enteritis in poultry.
*** Webinar *** An online webinar presented by Elanco and InnoCentive concerning Elanco's Grand Challenge Program will be held on October 20, 2016 at 10:30 AM (US Eastern Time). The webinar will include a question and answer session. Register in advance here: https://innocentive.webex.com/innocentive/j.php?RGID=re71ea91971dce8a5bd40cbb6d0d0b74c.
After registering, you will receive a confirmation email with a link to join the webinar. A recording will be attached to this Challenge for those who are unable to attend.
Source: InnoCentive Challenge ID: 9933891
Earlier this year, the American Heart Association (AHA), in partnership with Patient-Centered Outcomes Research Institute (PCORI), conducted a Challenge to hear patients' insights on how health decisions related to heart disease and stroke were made. After patients identified many areas of uncertainty, we are now turning to researchers and clinicians to address several of them through refinement into comparative effectiveness research questions that could benefit from precision medicine approaches. This is an Ideation Challenge with a guaranteed award for four submitters.
Source: InnoCentive Challenge ID: 9933836
Obstructive Sleep Apnea (OSA) affects millions of individuals in the United States and many more worldwide. Fortunately, an effective non-surgical treatment exists in the form of a continuous positive airway pressure (CPAP) device used while sleeping. Unfortunately, adherence to the use of a CPAP for people diagnosed with OSA lies in the 40-50% range despite past efforts to improve devices and educate patients. The Seeker is looking for innovative solutions for increasing adherence to CPAP treatment for OSA. Solutions may take a wide range of approaches to address the psychological, physical, or comfort issues faced by people who should be using a CPAP but are not.
Source: InnoCentive Challenge ID: 9933907